Form

Ionis Announces European Medicines Agency Accepts Marketing Authorization Application for Tofersen to Treat Rare Genetic Form of ALS

Ionis Announces European Medicines Agency Accepts Marketing Authorization Application for Tofersen to Treat Rare Genetic Form of ALS

Leave a Comment / Medicine / By

SOD1-ALS affects approximately 2% of people living with ALS worldwide1 If approved, tofersen would be the world’s first treatment to target a genetic cause of ALS EMA acceptance follows FDA acceptance of tofersen NDA earlier this year CARLSBAD, Calif., December 5, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the European Medicines …

Ionis Announces European Medicines Agency Accepts Marketing Authorization Application for Tofersen to Treat Rare Genetic Form of ALS Read More »

MEDICINE MAN TECHNOLOGIES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (Form 10-Q) | MarketScreener

Organicell Regenerative Medicine: Responds to Recent Promotional Activities as Demand from OTC Markets – Form 8-K | MarketScreener

Leave a Comment / Medicine / By

Organicell Regenerative Medicine, Inc. responds to recent promotional activities as requested by OTC markets Davie, Florida – November 21, 2022 – Organicell Regenerative Medicine, Inc. (OTCQB: OCEL) (“Organicell” or the “Company“) was requested by OTC Markets Group, Inc. (“OTC markets“) to release this statement on promotional activity regarding its common stock. On November 17, 2022, …

Organicell Regenerative Medicine: Responds to Recent Promotional Activities as Demand from OTC Markets – Form 8-K | MarketScreener Read More »

MIND MEDICINE (MINDMED) INC. Management report and analysis of the financial situation and operating results. (Form 10-Q) | MarketScreener

MIND MEDICINE (MINDMED) INC. Management report and analysis of the financial situation and operating results. (Form 10-Q) | MarketScreener

Leave a Comment / Medicine / By

The following discussion should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto included elsewhere in this Quarterly Report on Form 10-Q. This Quarterly Report on Form 10-Q, including the following sections, contains forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results and events …

MIND MEDICINE (MINDMED) INC. Management report and analysis of the financial situation and operating results. (Form 10-Q) | MarketScreener Read More »

MEDICINE MAN TECHNOLOGIES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (Form 10-Q) | MarketScreener

MEDICINE MAN TECHNOLOGIES, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (Form 10-Q) | MarketScreener

Leave a Comment / Medicine / By

The following discussion should be read in conjunction with our unaudited consolidated financial statements and notes thereto included herein and with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC. In addition to our historical unaudited condensed consolidated financial …

MEDICINE MAN TECHNOLOGIES, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (Form 10-Q) | MarketScreener Read More »